Oslo, November 10, 2016 - Reference is made to the announced in-depth company update Thursday 10 November 2016, 09.00-11.00am at Felix Konferansesenter at Aker Brygge, Bryggetorget 3, Oslo. The presentation is attached and it will also be available at PCI Biotech's webpage under News.
The Company will be represented by the Chairman Hans Peter Bøhn, Per Walday (CEO), Ronny Skuggedal (CFO) and Anders Høgset (CSO).
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead fimaChem programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For more information visit: www.pcibiotech.com
For further information, please contact:
Ronny Skuggedal, CFO
email: rs@pcibiotech.no
Mobile: +47 9400 5757
